Newsweek International  |  24 February 2017
THE WAR ON ALZHEIMER'S
This aggressive attempt to prevent Alzheimer’s rather than treating it is the most exciting new development in decades, as well as a radical departure for researchers and the pharmaceutical industry. Traditionally, drug companies have tested their therapies on patients who already have memory loss, trouble thinking and other signs of dementia. It’s been a losing tactic: More than ninety nine percent of all Alzheimer’s drugs have failed tests in the clinic, and the few that have made it to the market only ameliorate some symptoms. No single medicine has been shown to slow the relentless progression of the disease. However this new approach, even partial success an appreciable slowing of brain degeneration could have a big impact, says Dr. Reisa Sperling, a neurologist who directs the Center for Alzheimer’s Researc.
read more
read less
As a subscriber you'll receive the following benefits:
• A discount off the RRP of your magazine
• Your magazine delivered to your device each month
• You'll never miss an issue
• You’re protected from price rises that may happen later in the year
You'll receive 51 issues during a 1 year Newsweek International magazine subscription.
Note: Digital editions do not include the covermount items or supplements you would find with printed copies.
Articles in this issue
Below is a selection of articles in Newsweek International 24 February 2017.